about
HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approachLiquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discoverySerum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.Comprehensive proteomic analysis of the human milk proteome: contribution of protein fractionation.[Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer].Highly sensitive detection of melanoma based on serum proteomic profiling.Pemphigus vulgaris antigen mRNA quantification for the staging of sentinel lymph nodes in head and neck cancer.Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma.Use of autoantibodies to detect the onset of breast cancerImpact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencingCutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.Prion propagation in cultured cells.Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens.Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells.High-throughput detection of clinically targetable alterations using next-generation sequencing.Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids.High Prevalence of SXT/R391-Related Integrative and Conjugative Elements Carrying blaCMY-2 in Proteus mirabilis Isolates from Gulls in the South of FranceEvaluation of the SLOMYCO Sensititre(®) panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates.High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso.Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Identifying autoantibody signatures in cancer: a promising challenge.VIM-1 carbapenemase-producing Escherichia coli in gulls from southern France.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.FKBP family proteins as promising new biomarkers for cancer.Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes.Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy.KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissuesAn integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.Establishment and characterization of a cell line from human circulating colon cancer cells.A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute plAnti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016.Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approachesFirst Description of IncX3 Plasmids Carrying blaOXA-181 in Escherichia coli Clinical Isolates in Burkina Faso.Epstein-Barr virus DNA quantitation assessed by a real-time polymerase chain reaction in a case of Burkitt's lymphoma.Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
P50
Q28481613-870F8455-A85D-44FA-A199-64CBC6E34425Q30478449-3DE7BF74-711B-42D8-92E1-A9358F23135EQ33356491-FDFF2BD4-9B6A-45F6-9CC9-CB4A08CB30F8Q33358575-3EAC81C6-F501-4F19-8011-73F85C9019BBQ33385579-6039B072-4411-4818-A0D2-26C15380CECDQ33396595-23FF4A0E-DCEB-405E-B248-02CEEC237B25Q33418426-A41EC515-87FA-4B0F-BE2C-873785B421EAQ33620021-347608FD-DB42-4423-9AFE-FC87FB1A10EBQ33910073-D7976730-C440-4310-8DEF-F03E593B2150Q34037876-984A3AC3-30F5-421F-92C8-2398A63F6595Q34415439-06FFF9E6-D02B-444E-8BB8-8D1AE8F99820Q34469532-7A65F124-B99A-462E-B917-B314AAEE4846Q35381501-BD31B426-1BC7-48F2-87B4-88C12D32567AQ35548980-69E7DDE5-C4BC-46A1-8D8F-9DD60265CAC7Q36088228-0F8EC3E2-D44E-4499-A2B0-F6ABF44C1A1AQ36148358-2B2BB69E-0FC6-4DD9-9CED-A73983032228Q36312079-B51C2117-B564-49B6-8CE8-4FEDBBB55939Q36345358-493FF378-256B-4B88-A5C4-B80DADF3FA44Q36470088-C9DBFD79-749A-45BF-8143-0A6984AC2010Q36571845-5D5CFDAE-E871-4F7F-A029-B2CB21E31AA9Q36875804-ABFEEBA3-91AD-4EE7-A648-FC723B0F797CQ37251526-8340FBDA-E88A-4F01-ABD7-C8572922B3E8Q37404105-442CE8D3-E4D7-4553-AEFF-925B58761A9FQ37579900-73B3571E-1376-4587-96BF-99630BC39EC7Q37639181-746FCFFD-3ED1-4C76-910E-53ED5C53C931Q37690677-6064B294-207A-4DAD-A918-1F1D5076B370Q37868159-2F10160F-FC01-49E3-8DAC-A798D5CAD6FEQ38081954-D6A63713-CF33-4EF3-9CC0-1F178F7682FEQ38286519-ADB8198A-4F48-4695-BF58-2471F8C203A3Q38409695-7108D978-9F91-4AD8-AFED-375C4C42B5BDQ38771754-F813CB72-B1BA-45BE-836F-898C1080A8E5Q38919576-3BD8365E-9503-4127-B62D-20F4937D125AQ39067796-54C09723-9C42-4FF5-80C7-F18EFB09690AQ39719132-59927C4A-09FA-4794-95DF-4A7A1F09A22EQ39953442-A24C3F80-6FAE-4A24-8C38-30C128F65120Q40137781-03EC41F9-46E2-4110-8731-81028183BA65Q42286165-6C251F7A-670C-4712-9CF3-78B0165D3D3BQ42797318-C138E255-37BE-4226-85F3-C5410B558CCBQ45737167-98032EDE-257A-4461-852E-411D7E4483D7Q45936703-CBA9448C-3371-4C66-BCA4-041569E40563
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jérome Solassol
@ast
Jérome Solassol
@en
Jérome Solassol
@es
Jérome Solassol
@nl
type
label
Jérome Solassol
@ast
Jérome Solassol
@en
Jérome Solassol
@es
Jérome Solassol
@nl
prefLabel
Jérome Solassol
@ast
Jérome Solassol
@en
Jérome Solassol
@es
Jérome Solassol
@nl
P106
P31
P496
0000-0002-0293-6158